Novel agents for the treatment of polycythemia vera: an insight into preclinical research and early phase clinical trials.

ABSTRACT:

Introduction

Current treatment for polycythemia vera (PV) is limited and primarily targets thrombosis risk. Agents targeting distinct mechanisms of action within myeloproliferation are undergoing clinical evaluation to optimize efficacy, improve tolerance and augment long term disease complications.

Area covered

This article reviews the current data from completed early phase clinical trials in PV, either as monotherapy or in combination with the few currently approved agents.

Expert opinion

There remains an opportunity in PV management to improve efficacy and decrease risk of disease progression. Evolving data from use of long acting interferons are serving to clarifying the potential front line role of this therapy. JAK2 inhibition has made a significant impact on d

SUBMITTER: Padrnos L 

PROVIDER: S-EPMC8895353 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature